Integration of Biomaterials for Gene Therapy | Agenda Bookshop Skip to content
Please note that books with a 10-20 working days delivery time will not arrive before Christmas.
Please note that books with a 10-20 working days delivery time will not arrive before Christmas.
Age Group_Uncategorized
Age Group_Uncategorized
automatic-update
B01=Neelam Jain
B01=Rishabha Malviya
B01=Sonali Sundram
Category1=Non-Fiction
Category=MJZ
Category=TCBG
Category=TGM
COP=United States
Delivery_Delivery within 10-20 working days
Language_English
PA=Available
Price_€100 and above
PS=Active
softlaunch

Integration of Biomaterials for Gene Therapy

English

INTEGRATION OF BIOMATERIALS FOR GENE THERAPY

Brings industrial practitioners and researchers together to discuss how the deeper integration of biomaterial platforms could play a significant role in enabling breakthroughs in the application of gene editing for the treatment of human disease.

This book comprises research and review articles from leading researchers with multidisciplinary experience. It discusses many broad topics, including nanoparticle-enabled gene therapy, inorganic nanocarrier-based gene delivery, non-viral delivery of nucleic acid, biocompatible hydrogels, silk, and polysaccharides-based gene delivery. Other gene delivery topics discussed include the use of smart and engineered biomaterials, combined therapy with growth factors and cell transportation, and the prospects and challenges in the treatment of different diseases, including cancer.

This book bridges the knowledge of pharmaceutics, engineering, basic science, and clinical research fields in a way that will help the research community expedite the clinical application of these therapies for various diseases and conditions.

Audience

A broad range of researchers, scientists, and engineers in diverse fields such as materials science, biomedicine, biomedical engineering, biology, chemistry, physics, biotechnology, pharmacology, toxicology, and formulation scientists.

See more
Current price €174.79
Original price €183.99
Save 5%
Age Group_Uncategorizedautomatic-updateB01=Neelam JainB01=Rishabha MalviyaB01=Sonali SundramCategory1=Non-FictionCategory=MJZCategory=TCBGCategory=TGMCOP=United StatesDelivery_Delivery within 10-20 working daysLanguage_EnglishPA=AvailablePrice_€100 and abovePS=Activesoftlaunch
Delivery/Collection within 10-20 working days
Product Details
  • Weight: 826g
  • Publication Date: 02 May 2024
  • Publisher: John Wiley & Sons Inc
  • Publication City/Country: United States
  • Language: English
  • ISBN13: 9781394174737

About

Rishabha Malviya PhD is an associate professor in the Department of Pharmacy School of Medical and Allied Sciences Galgotias University. He has authored more than 150 research/review papers for national/international journals. He has been granted more than 10 patents from different countries while a further 40 patents are published/under evaluation. He has edited multiple volumes for Wiley-Scrivener. Sonali Sundram completed her M. Pharm from Dr. A. P. J. Abdul Kalam Technical University Lucknow India and she is now a research scientist at King Georges Medical University Lucknow as well as an assistant professor at Galgotias University Greater Noida. She has more than 8 patents to her credit and edited 6 books with international publishers. Neelam Jain PhD holds a Doctorate in Pharmaceutics (specialization in Nanomedicine) from the Institute of Foreign Trade and Management Moradabad Uttar Pradesh India. She has over 11 years of research and teaching experience and is now an associate professor at the Faculty of Pharmacy Oriental University Indore India. She has been working on an array of projects relating to nanomedicine gene therapy nanotechnology and pharmacology. She published more than 50 research/review papers in nanomedicine drug delivery and formulation technology in peer-reviewed journals and books.

Customer Reviews

Be the first to write a review
0%
(0)
0%
(0)
0%
(0)
0%
(0)
0%
(0)
We use cookies to ensure that we give you the best experience on our website. If you continue we'll assume that you are understand this. Learn more
Accept